Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Tags:
StartUps and SMEs Research and Development Strategies Pricing Strategies

At Paragon, Jeffrey Aronin Has Launched His Next Act – Or Eight Of Them

  • News

Executive Summary

Jeffrey Aronin, who presided over Marathon Pharmaceuticals during a drug-pricing kerfuffle that drew congressional scrutiny, has built a portfolio of new drug companies at Paragon Biosciences.

You may also be interested in...



Keeping Track: A Quintet Of Novel Approvals

The latest drug development news and highlights from our US FDA Performance Tracker. 

Putting The 'Big' Back In PhRMA: New Membership Criteria Pares Ranks

PhRMA eliminates 42% of members in conjunction with new membership eligibility criteria stipulating minimum R&D investment levels.

Amid Pricing Criticism, Marathon 'Pausing' Emflaza Launch

Company plans to meet with caregivers and consider other options before moving forward.

Table

View full table

Related Content

Scrip Pink Sheet

Topics

Related Companies

Related Deals

Tags:
StartUps and SMEs Research and Development Strategies Pricing Strategies
UsernamePublicRestriction

Register

SC141447

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By